Skip to content
Goldline Pharmaceutical logo

Goldline Pharmaceutical

544759 BSE
₹29.98

Close ·

P/E
9.37
View as Markdown
MCP
Close 2 Nov 2026 ₹29.98 −26.79 −47.2% since 19 May 2026
Start ₹56.77

Key Fundamentals

SME

Price-based figures at the close · TTM

ROCE
30.60%
Debt to Equity
0.88
EPS (TTM)
₹3.20
Book Value
₹25.05
Market Cap
—
P/E (TTM)
9.37
P/B
1.20
ROE
39.40%
Dividend Yield
0.00%
EBITDA
₹6.90 Cr
52W High
₹60.00
52W Low
₹28.13

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish991
OscillatorsNeutral171
Moving AveragesStrong Bearish820

Key readings

RSI (14)
39.41
Neutral
MACD (12,26,9)
−1.20
Bullish
SMA (50)
35.47
Bearish
SMA (200)
—
Neutral

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
3Y+16.48%
1Y+11.32%

Net profit

Net profit growth by window
3Y+151.17%
1Y+45.58%

Operating cash flow

Operating cash flow growth by window
3Y+5.54%
1Y−11.64%

Operating margin· change in pp

Operating margin growth by window
3Y+10.53 pp
1Y+0.78 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2023₹19.73 Cr
Mar 2024₹23.48 Cr
Mar 2025₹28.01 Cr
Mar 2026₹31.18 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2023₹0.26 Cr
Mar 2024₹1.81 Cr
Mar 2025₹2.83 Cr
Mar 2026₹4.12 Cr

Half-yearly Results

₹ Cr
544759 half-yearly results, ₹ crore
Particulars Sep 2025Mar 2026
Sales
13.89
17.31
Expenses
11.25
13
Operating Profit
2.64
4.31
OPM %
19.01%
24.9%
Other Income
0
0
Interest
0.67
0.65
Depreciation
0.12
0.12
PBT
1.85
3.54
Tax %
26.49%
21.75%
Net Profit
1.36
2.76
EPS (₹)
1.97
4

Profit & Loss

₹ Cr
544759 profit and loss, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Sales
19.73
23.48
28.01
31.18
Expenses
17.32
19.14
21.86
24.09
Operating Profit
2.41
4.34
6.15
7.09
OPM %
12.21%
18.48%
21.96%
22.74%
Other Income
−0.2
−0.04
−0.09
0
Interest
1.63
1.61
1.95
1.46
Depreciation
0.18
0.16
0.25
0.24
PBT
0.4
2.53
3.86
5.39
Tax %
37.5%
28.46%
26.42%
23.38%
Net Profit
0.26
1.81
2.83
4.12
EPS (₹)
1.3
7.87
4.1
5.97
Div. Payout %
0%
0%
0%
0%

Balance Sheet

₹ Cr
544759 balance sheet, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2.3
6.9
6.9
Reserves
2.08
3.76
1.55
5.54
Borrowings
12.64
12.94
12.85
10.97
Other Liabilities
2.67
3.93
4.88
5.47
Total Liabilities
19.39
22.93
26.18
28.88
Fixed Assets
2.5
2.95
2.89
2.71
CWIP
0
0.45
0
0
Investments
0.07
0.03
0.03
0.03
Other Assets
16.82
19.5
23.26
26.14
Total Assets
19.39
22.93
26.18
28.88

Cash Flow

₹ Cr
544759 cash flow, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2.39
2.92
3.18
2.81
Investing
−1.04
−1.11
0.16
−0.06
Financing
−1.44
−1.08
−2.89
−3.4
Net Cash Flow
−0.09
0.74
0.45
−0.65
Free Cash Flow
1.38
1.81
3.35
2.75
CFO/OP
101
72
66
53

Ratios

544759 financial ratios, annual
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
160
150
139
189
Inventory Days
336
450
229
202
Days Payable
54.47
98.62
69.62
60.29
Cash Conversion Cycle
441
501
299
331
Working Capital Days
144
133
134
156
ROCE %
—
23.4%
29.28%
30.64%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Goldline Pharmaceutical insights

53 extracted metrics across FY17–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 59.54%
  • Public 34.32%
  • Others 5.73%
  • FIIs 0.31%
  • DIIs 0.09%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Goldline Pharmaceutical

Where is Goldline Pharmaceutical (GLPL) listed?
Goldline Pharmaceutical trades under code 544759 on the BSE.
What is the PE ratio of Goldline Pharmaceutical?
Goldline Pharmaceutical trades at a PE ratio of 9.37 as of 2 Nov 2026, on earnings per share of ₹3.2, against a book value of ₹25.05 per share.
What is the 52-week high and low of Goldline Pharmaceutical?
Over the last 52 weeks Goldline Pharmaceutical has traded between ₹28.13 and ₹60 as of 2 Nov 2026.
What is the Return on Equity (ROE) of Goldline Pharmaceutical?
Goldline Pharmaceutical reported a return on equity of 39.40%. Its debt-to-equity ratio is 0.88.

Company Information

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544759.md for Goldline Pharmaceutical: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month